0001650664-24-000013.txt : 20240305
0001650664-24-000013.hdr.sgml : 20240305
20240305195442
ACCESSION NUMBER: 0001650664-24-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240302
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mei Baisong
CENTRAL INDEX KEY: 0001938499
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37687
FILM NUMBER: 24723734
MAIL ADDRESS:
STREET 1: C/O EDITAS MEDICINE, INC.
STREET 2: 1 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Editas Medicine, Inc.
CENTRAL INDEX KEY: 0001650664
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464097528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-401-9000
MAIL ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
wk-form4_1709686469.xml
FORM 4
X0508
4
2024-03-02
0
0001650664
Editas Medicine, Inc.
EDIT
0001938499
Mei Baisong
C/O EDITAS MEDICINE, INC.
11 HURLEY ST.
CAMBRIDGE
MA
02141
0
1
0
0
SVP, CHIEF MEDICAL OFFICER
1
Common Stock
2024-03-02
4
A
0
50900
0
A
122955
D
Common Stock
2024-03-02
4
A
0
19458
0
A
142413
D
Common Stock
2024-03-02
4
A
0
19457
0
A
161870
D
Common Stock
2024-03-04
4
S
0
20327
9.4173
D
141543
D
Stock Option (right to buy)
10.53
2024-03-02
4
A
0
152800
0
A
2034-03-01
Common Stock
152800
152800
D
The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022.
Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022.
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022 and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.
/s/ Baisong Mei
2024-03-05